Welcome to our dedicated page for Channel Therapeutics Corporation news (Ticker: CHRO), a resource for investors and traders seeking the latest updates and insights on Channel Therapeutics Corporation stock.
Channel Therapeutics Corporation (CHRO) is a clinical-stage biotech pioneer developing non-opioid pain therapies by targeting the NaV1.7 sodium channel. This page provides investors and industry professionals with timely updates on the company’s clinical trials, research breakthroughs, and strategic initiatives.
Access the latest press releases, financial reports, and regulatory milestones in one centralized location. Track progress across key programs like CC8464 (neuropathic pain) and CT2000 (ocular pain), along with partnership announcements and scientific publications.
Our curated news collection ensures you stay informed on CHRO’s advancements in non-addictive pain management without promotional bias. Bookmark this page for efficient monitoring of clinical developments, FDA updates, and market positioning in the biotech sector.
Chromocell Therapeutics (NYSE American: CHRO), a pioneer in non-opioid pain treatment development, has announced a stock repurchase plan of up to $250,000 of its common stock. This represents approximately 23% of the non-affiliate float based on the August 6, 2024 closing price. The plan, which is discretionary and can be modified or terminated at any time, aims to enhance stockholder value.
CEO Frank Knuettel stated that while the company remains focused on allocating capital to clinical and pre-clinical programs, they believe the current stock price doesn't reflect their progress in developing drugs for neuropathic and chronic pain. The company views its stock as an attractive investment opportunity and expects to make announcements in the coming months supporting their drug development efforts.
Chromocell Therapeutics (NYSE American: CHRO), a leader in non-opioid pain treatment development, has announced its participation in the Virtual Investor Lunch Break Series. The event, titled 'The Chromocell Opportunity,' is scheduled for Thursday, July 18, 2024, at 12:00 PM ET.
Frank Knuettel II, serving as both CEO and CFO, will present a corporate overview and business outlook. The session will include a live Q&A segment, allowing attendees to submit questions. A live video webcast will be available on the company's website, with a replay accessible for 90 days following the event.
Chromocell Therapeutics , listed as CHRO on NYSE American, will have its CEO present at Alliance Global Partners Healthcare Company Showcase on May 21, 2024. The conference will feature top healthcare companies discussing industry catalysts and future trends. Investors can attend the 20-minute 'fireside chat' style presentations online.
FAQ
What is the current stock price of Channel Therapeutics Corporation (CHRO)?
What is the market cap of Channel Therapeutics Corporation (CHRO)?
